Ocugen Stock Forecast, Price & News

+0.20 (+2.92 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume13.46 million shs
Average Volume57.90 million shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OCGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter.

Ocugen logo

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.


Ocugen (OCGN) Scheduled to Post Quarterly Earnings on Friday
Ocugen (OCGN) Scheduled to Post Quarterly Earnings on Friday
July 31, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.73 out of 5 stars

Medical Sector

815th out of 1,309 stocks

Biological Products, Except Diagnostic Industry

122nd out of 179 stocks

Analyst Opinion: 2.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Ocugen (NASDAQ:OCGN) Frequently Asked Questions

Is Ocugen a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ocugen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCGN, but not buy additional shares or sell existing shares.
View analyst ratings for Ocugen
or view top-rated stocks.

What stocks does MarketBeat like better than Ocugen?

Wall Street analysts have given Ocugen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ocugen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ocugen's next earnings date?

Ocugen is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Ocugen

How can I listen to Ocugen's earnings call?

Ocugen will be holding an earnings conference call on Friday, August 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Ocugen's earnings last quarter?

Ocugen, Inc. (NASDAQ:OCGN) issued its quarterly earnings results on Friday, May, 7th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.50 by $0.54.
View Ocugen's earnings history

How has Ocugen's stock price been impacted by COVID-19?

Ocugen's stock was trading at $0.3612 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OCGN stock has increased by 1,851.8% and is now trading at $7.05.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OCGN?

5 brokers have issued 12 month price targets for Ocugen's stock. Their forecasts range from $4.50 to $11.00. On average, they expect Ocugen's share price to reach $7.66 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts' price targets for Ocugen
or view top-rated stocks among Wall Street analysts.

Who are Ocugen's key executives?

Ocugen's management team includes the following people:
  • Dr. Shankar Musunuri M.B.A., Ph.D., MBA, Co-Founder, Chairman & CEO (Age 57, Pay $780.67k)
  • Dr. Uday B. Kompella Ph.D., Co-founder & Independent Director (Age 54, Pay $44.77k)
  • Mr. Sanjay S. Subramanian M.B.A., Chief Accounting Officer, CFO, Treasurer, Head of Corp. Devel. & Corp. Sec. (Age 45, Pay $511.15k)
  • Ms. Zara Gaudioso, Head of HR
  • Dr. Vijay Tammara, Sr. VP of Regulatory & Quality (Age 62)
  • Dr. Arun Upadhyay Ph.D., Head of Research, Devel. & Discovery
  • Dr. Bruce D. Forrest B.S., M.B.A., M.D., Acting Chief Medical Officer & Vaccine Scientific Advisory Board Member (Age 58)
  • Mr. J. P. Gabriel, Sr. VP of Manufacturing & Supply Chain
  • Ms. Jessica Crespo CPA, CPA, Corp. Controller

Who are some of Ocugen's key competitors?

What other stocks do shareholders of Ocugen own?

What is Ocugen's stock symbol?

Ocugen trades on the NASDAQ under the ticker symbol "OCGN."

Who are Ocugen's major shareholders?

Ocugen's stock is owned by a number of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (0.10%), New York State Common Retirement Fund (0.08%), Victory Capital Management Inc. (0.03%), Arizona State Retirement System (0.03%), Golden Green Inc. (0.02%) and Cutler Group LP (0.00%). Company insiders that own Ocugen stock include Christopher Dold, Daniel Purefoy, Howard C Draft, Junge Zhang, Kirsten Castillo, Manish Potti, Prabhavathi Fernandes, Ramesh Kumar, Sanjay Subramanian, Shankar Musunuri, Uday Kompella and Vijay Tammara.
View institutional ownership trends for Ocugen

Which major investors are buying Ocugen stock?

OCGN stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., New York State Common Retirement Fund, Arizona State Retirement System, Golden Green Inc., Victory Capital Management Inc., Cutler Group LP, Zurcher Kantonalbank Zurich Cantonalbank , and Creative Financial Designs Inc. ADV. Company insiders that have bought Ocugen stock in the last two years include Howard C Draft, Junge Zhang, Kirsten Castillo, Sanjay Subramanian, and Shankar Musunuri.
View insider buying and selling activity for Ocugen
or or view top insider-buying stocks.

How do I buy shares of Ocugen?

Shares of OCGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocugen's stock price today?

One share of OCGN stock can currently be purchased for approximately $7.05.

How much money does Ocugen make?

Ocugen has a market capitalization of $1.40 billion and generates $42.62 million in revenue each year. The company earns $-21,820,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

How many employees does Ocugen have?

Ocugen employs 15 workers across the globe.

What is Ocugen's official website?

The official website for Ocugen is

Where are Ocugen's headquarters?

Ocugen is headquartered at 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355.

How can I contact Ocugen?

Ocugen's mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The company can be reached via phone at 484-328-4701 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.